Matches in SemOpenAlex for { <https://semopenalex.org/work/W2905464064> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2905464064 endingPage "S1072" @default.
- W2905464064 startingPage "S1072" @default.
- W2905464064 abstract "This phase I study aimed to establish the feasible dose of Apatinib in combination with pemetrexed plus carboplatin as first-line therapy for EGFR-negative stage IV non-squamous non-small-cell lung cancer (NSCLC). Using a 3+3 dose-reduction design, patients received oral Apatinib at four dose levels: 750 mg qd, 500 mg qd, 500 mg/day 2 weeks on/1 week off schedule (schedule 2/1) or 250mg qd. Pemetrexed (500 mg/m2) plus carboplatin (AUG=5) was administered every 3 weeks. The feasible dose was determined based on cycle 1 dose-limiting toxicities (DLT); other assessments included safety and antitumor activity according to response evaluation criteria in solid tumors. A total of 12 patients were enrolled and cycle 1 DLTs were observed in two patients at 750 mg qd treatment (both Grade 3 hypertension), two patients at 500 mg qd (Grade 3 hypertension and Grade 3 hand-foot syndrome), and only one of six patients at 500 mg/day schedule 2/1 (Grade 3 hypertension). The most frequently drug-related adverse events were hematological toxicity, hypertension, hand-foot syndrome and hepatic transaminases elevation. Partial response was observed in 4 patients of 11 evaluable patients (ORR 36.4%), and 6 patients exhibited stable disease (DCR 90.9%). In patients with advanced non-squamous NSCLC, the feasible dose of Apatinib given with standard-dose pemetrexed and carboplatin was 500 mg/day schedule 2/1. The schedule was generally well tolerated and demonstrated promising clinical benefit in NSCLC." @default.
- W2905464064 created "2018-12-22" @default.
- W2905464064 creator A5006882159 @default.
- W2905464064 creator A5032988856 @default.
- W2905464064 creator A5053307667 @default.
- W2905464064 creator A5061645783 @default.
- W2905464064 creator A5067979680 @default.
- W2905464064 creator A5071623431 @default.
- W2905464064 creator A5072270215 @default.
- W2905464064 creator A5076344513 @default.
- W2905464064 creator A5084733946 @default.
- W2905464064 creator A5086334551 @default.
- W2905464064 date "2018-12-01" @default.
- W2905464064 modified "2023-09-27" @default.
- W2905464064 title "P066 A Phase I Study of Apatinib Combined with Pemetrexed and Carboplatin in Untreated EGFR-Negative Stage IV Non-Squamous NSCLC" @default.
- W2905464064 doi "https://doi.org/10.1016/j.jtho.2018.10.081" @default.
- W2905464064 hasPublicationYear "2018" @default.
- W2905464064 type Work @default.
- W2905464064 sameAs 2905464064 @default.
- W2905464064 citedByCount "0" @default.
- W2905464064 crossrefType "journal-article" @default.
- W2905464064 hasAuthorship W2905464064A5006882159 @default.
- W2905464064 hasAuthorship W2905464064A5032988856 @default.
- W2905464064 hasAuthorship W2905464064A5053307667 @default.
- W2905464064 hasAuthorship W2905464064A5061645783 @default.
- W2905464064 hasAuthorship W2905464064A5067979680 @default.
- W2905464064 hasAuthorship W2905464064A5071623431 @default.
- W2905464064 hasAuthorship W2905464064A5072270215 @default.
- W2905464064 hasAuthorship W2905464064A5076344513 @default.
- W2905464064 hasAuthorship W2905464064A5084733946 @default.
- W2905464064 hasAuthorship W2905464064A5086334551 @default.
- W2905464064 hasBestOaLocation W29054640641 @default.
- W2905464064 hasConcept C126322002 @default.
- W2905464064 hasConcept C126894567 @default.
- W2905464064 hasConcept C143998085 @default.
- W2905464064 hasConcept C197934379 @default.
- W2905464064 hasConcept C2776256026 @default.
- W2905464064 hasConcept C2776694085 @default.
- W2905464064 hasConcept C2777240266 @default.
- W2905464064 hasConcept C2778239845 @default.
- W2905464064 hasConcept C2778570526 @default.
- W2905464064 hasConcept C2779984678 @default.
- W2905464064 hasConcept C2780668389 @default.
- W2905464064 hasConcept C2781451048 @default.
- W2905464064 hasConcept C29730261 @default.
- W2905464064 hasConcept C31760486 @default.
- W2905464064 hasConcept C71924100 @default.
- W2905464064 hasConcept C90924648 @default.
- W2905464064 hasConceptScore W2905464064C126322002 @default.
- W2905464064 hasConceptScore W2905464064C126894567 @default.
- W2905464064 hasConceptScore W2905464064C143998085 @default.
- W2905464064 hasConceptScore W2905464064C197934379 @default.
- W2905464064 hasConceptScore W2905464064C2776256026 @default.
- W2905464064 hasConceptScore W2905464064C2776694085 @default.
- W2905464064 hasConceptScore W2905464064C2777240266 @default.
- W2905464064 hasConceptScore W2905464064C2778239845 @default.
- W2905464064 hasConceptScore W2905464064C2778570526 @default.
- W2905464064 hasConceptScore W2905464064C2779984678 @default.
- W2905464064 hasConceptScore W2905464064C2780668389 @default.
- W2905464064 hasConceptScore W2905464064C2781451048 @default.
- W2905464064 hasConceptScore W2905464064C29730261 @default.
- W2905464064 hasConceptScore W2905464064C31760486 @default.
- W2905464064 hasConceptScore W2905464064C71924100 @default.
- W2905464064 hasConceptScore W2905464064C90924648 @default.
- W2905464064 hasIssue "12" @default.
- W2905464064 hasLocation W29054640641 @default.
- W2905464064 hasOpenAccess W2905464064 @default.
- W2905464064 hasPrimaryLocation W29054640641 @default.
- W2905464064 hasRelatedWork W1607236184 @default.
- W2905464064 hasRelatedWork W2013653877 @default.
- W2905464064 hasRelatedWork W2037915643 @default.
- W2905464064 hasRelatedWork W2066950280 @default.
- W2905464064 hasRelatedWork W2358450743 @default.
- W2905464064 hasRelatedWork W2767892815 @default.
- W2905464064 hasRelatedWork W2802659363 @default.
- W2905464064 hasRelatedWork W3029907145 @default.
- W2905464064 hasRelatedWork W3045247625 @default.
- W2905464064 hasRelatedWork W2091616146 @default.
- W2905464064 hasVolume "13" @default.
- W2905464064 isParatext "false" @default.
- W2905464064 isRetracted "false" @default.
- W2905464064 magId "2905464064" @default.
- W2905464064 workType "article" @default.